Previous studies in multiple cancer types, using various methods to downregulate cFLIP expression, have demonstrated similar effects on the enhancement of TRAIL signalling, for e.g., cycloheximide in renal cancer cells [49], histone deacetylase inhibitors in glioma cells [44] and R-roscovitine in breast cancer cells [50]. This evidence concerns the gene TNFSF10 and breast cancer.